IL25 and colonic neoplasm: Interestingly, there was greater overall tumor burden in the colons of mice treated with the α-IL-25 antibody (16.79 ± 1.95 N = 14 versus 9.61 ± 0.87 N = 12 in control group, p = 0.004) (Fig. 1D,E), suggesting that IL-25 is limiting the growth and development of colonic tumors.